1. Home
  2. NVCR vs PLUS Comparison

NVCR vs PLUS Comparison

Compare NVCR & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • PLUS
  • Stock Information
  • Founded
  • NVCR 2000
  • PLUS 1990
  • Country
  • NVCR Switzerland
  • PLUS United States
  • Employees
  • NVCR 1488
  • PLUS N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • PLUS Retail: Computer Software & Peripheral Equipment
  • Sector
  • NVCR Health Care
  • PLUS Technology
  • Exchange
  • NVCR Nasdaq
  • PLUS Nasdaq
  • Market Cap
  • NVCR 1.4B
  • PLUS 1.9B
  • IPO Year
  • NVCR 2015
  • PLUS 1996
  • Fundamental
  • Price
  • NVCR $12.72
  • PLUS $74.63
  • Analyst Decision
  • NVCR Buy
  • PLUS
  • Analyst Count
  • NVCR 7
  • PLUS 0
  • Target Price
  • NVCR $28.79
  • PLUS N/A
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • PLUS 140.8K
  • Earning Date
  • NVCR 10-29-2025
  • PLUS 11-11-2025
  • Dividend Yield
  • NVCR N/A
  • PLUS 1.34%
  • EPS Growth
  • NVCR N/A
  • PLUS 9.38
  • EPS
  • NVCR N/A
  • PLUS 4.46
  • Revenue
  • NVCR $630,160,000.00
  • PLUS $2,170,452,000.00
  • Revenue This Year
  • NVCR $6.68
  • PLUS $7.12
  • Revenue Next Year
  • NVCR $7.01
  • PLUS N/A
  • P/E Ratio
  • NVCR N/A
  • PLUS $16.69
  • Revenue Growth
  • NVCR 14.58
  • PLUS N/A
  • 52 Week Low
  • NVCR $10.87
  • PLUS $53.83
  • 52 Week High
  • NVCR $34.13
  • PLUS $106.98
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 53.05
  • PLUS 60.18
  • Support Level
  • NVCR $11.98
  • PLUS $70.02
  • Resistance Level
  • NVCR $12.83
  • PLUS $74.88
  • Average True Range (ATR)
  • NVCR 0.56
  • PLUS 1.88
  • MACD
  • NVCR 0.16
  • PLUS 0.20
  • Stochastic Oscillator
  • NVCR 53.43
  • PLUS 95.70

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About PLUS ePlus inc.

ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.

Share on Social Networks: